Your browser is no longer supported. Please, upgrade your browser.
Settings
IKNA [NASD]
Ikena Oncology, Inc.
Index- P/E- EPS (ttm)- Insider Own0.10% Shs Outstand35.85M Perf Week-7.06%
Market Cap412.78M Forward P/E- EPS next Y-1.58 Insider Trans0.00% Shs Float31.36M Perf Month-24.48%
Income- PEG- EPS next Q-0.36 Inst Own82.80% Short Float4.71% Perf Quarter-51.02%
Sales9.44M P/S43.72 EPS this Y-163.20% Inst Trans0.20% Short Ratio8.92 Perf Half Y-
Book/sh6.35 P/B1.70 EPS next Y45.10% ROA- Target Price- Perf Year-
Cash/sh7.35 P/C1.47 EPS next 5Y- ROE- 52W Range10.47 - 37.61 Perf YTD-66.25%
Dividend- P/FCF- EPS past 5Y- ROI44.00% 52W High-71.28% Beta-
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low3.15% ATR1.48
Employees33 Current Ratio9.40 Sales Q/Q-67.90% Oper. Margin- RSI (14)39.36 Volatility10.18% 12.77%
OptionableNo Debt/Eq0.00 EPS Q/Q19.90% Profit Margin- Rel Volume0.35 Prev Close11.18
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume165.68K Price10.80
Recom1.50 SMA20-15.29% SMA50-26.83% SMA200-38.78% Volume57,864 Change-3.40%
May-05-21Resumed Credit Suisse Outperform $30
Apr-26-21Resumed Credit Suisse Outperform $30
Apr-20-21Initiated William Blair Outperform
Apr-20-21Initiated Jefferies Buy
Apr-20-21Initiated Credit Suisse Outperform $30
Jul-08-21 07:00AM  
Jun-26-21 05:18AM  
May-26-21 07:00AM  
May-13-21 07:00AM  
Apr-15-21 07:00AM  
Mar-30-21 04:05PM  
Mar-25-21 08:55PM  
Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.